SureTrader Advertisement Advertisement Advertisement
Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator TREND1, conix, MadHatter326, KingDMC, $Pistol Pete$
Search This Board:
Last Post: 10/5/2015 4:05:46 PM - Followers: 320 - Board type: Free - Posts Today: 25


About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at:


Board of Directors

Alfred E. Mann

Alfred E. Mann has been one of our directors since April 1999, our Chairman of the Board since December 2001 and our Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio


Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge  A good forum for discussion on Mankind

MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.;;




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MNKD News: MannKind to Present at Aegis Capital Corp. 2015 Growth Conference 09:00 AM
MNKD News: Scanning the Pulse of the Healthcare Stocks - ZIOPHARM Oncology, VIVUS, Keryx Biopharmaceuticals, MannKind and Ovascience 09/30/2015 12:56:00 PM
MNKD News: Technical Briefing on Biotechnology Equities -- MannKind, Novavax, Incyte, BioMarin Pharma, and Sangamo Biosciences 09/23/2015 08:06:00 AM
MNKD News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 09/04/2015 05:07:42 PM
MNKD News: Current Report Filing (8-k) 09/04/2015 05:04:14 PM
News News Alert: MannKind to Present at Aegis Capital Corp. 2015 Growth Conference 10/05/2015 09:00:00 AM
#14871  Sticky Note MNKD SHORT INTEREST--As of 9/15/2015 ---126,661,452 shares conix 09/30/15 03:57:35 PM
#13561  Sticky Note $MNKD MannKind Relies on 'Death Spiral' Fi $Pistol Pete$ 07/29/15 06:48:01 PM
#8377  Sticky Note Not Looking Good For MNKD! MadHatter326 02/13/15 02:37:35 PM
#15097   Just look at the R2000 futures ...going up TREND1 10/05/15 03:56:26 PM
#15096   Now that is good sold support for AFREZZA .... TREND1 10/05/15 03:50:33 PM
#15095   Guarantee news over the next two weeks and Hypi 10/05/15 03:45:45 PM
#15094   Hey how about one positive post for the TREND1 10/05/15 03:38:34 PM
#15093   MNKD 10 MINUTES TREND1 10/05/15 03:08:22 PM
#15092   IBB by Art Hill TREND1 10/05/15 02:55:04 PM
#15091   What would be positive for MNKD ? TREND1 10/05/15 02:30:42 PM
#15090   > The world’s most hated man this week DownWithPumpers 10/05/15 02:29:31 PM
#15089   I was just thinking I am going to tyfoidhana 10/05/15 02:13:50 PM
#15086   Maybe that is how mannkind will declare BK TREND1 10/05/15 12:32:38 PM
#15085   I knew something was up over there. Great Denise Chanterelle 10/05/15 12:22:01 PM
#15083   uT oH iHub will need to install seatbelts.. mc67 10/05/15 11:57:36 AM
#15082   IBB trading like slum. No surprise bios aren't KingDMC 10/05/15 11:07:43 AM
#15081   EMA20=3.41 A close above 3.41 put fear in the TREND1 10/05/15 11:02:19 AM
#15080   Short-term bullish at the moment TREND1 10/05/15 10:10:28 AM
#15079   Short term KingDMC 10/05/15 10:08:57 AM
#15078   Question long-term medium term short-term? TREND1 10/05/15 10:07:30 AM
#15077   Can you confirm MNKD is bullish? I'll wait.. KingDMC 10/05/15 09:51:45 AM
#15076   Hey hey hey green baby. KingDMC 10/05/15 09:48:31 AM
#15075   Corp. 2015 Growth Conference Source: GlobeNewswire Inc. MannKind Corporation ( KingDMC 10/05/15 09:06:15 AM
#15074   Hypi quote ..................................................................................... TREND1 10/05/15 12:42:08 AM
#15073   Hey what happened to BK, Dilution and SNY Hypi 10/04/15 10:01:27 PM
#15072   GB wins. 4 - 0 now... Denise Chanterelle 10/04/15 09:32:23 PM
#15071   Redskins win + Penn State wins = great KingDMC 10/04/15 08:57:15 PM
#15070   MNKD = Bullish. Perfect timing right when the KingDMC 10/04/15 06:06:49 PM
#15069   MNKD closed over $3.25. We are bullish folks. KingDMC 10/04/15 06:06:02 PM
#15068   Well stated Tyfoidhana. Aloha. Denise Chanterelle 10/04/15 05:55:27 PM
#15066   Haha right on! KingDMC 10/04/15 04:22:45 PM
#15065   Well the good news is This isn't shark tyfoidhana 10/04/15 04:12:33 PM
#15061   Possible if BoA doesn't returns 9 M shares Cave In Temptor 10/04/15 03:53:41 PM
#15060   On the Afrezza sales front, which has been Denise Chanterelle 10/04/15 03:50:08 PM
#15059   ethically, BoA has toyed with bankruptcy for a Cave In Temptor 10/04/15 03:50:01 PM
#15054   Trend, You said: "A close above 3.25 would be KingDMC 10/04/15 02:55:43 PM
#15052   Do you think a judge will declare BOA Denise Chanterelle 10/04/15 02:34:38 PM
#15051   BoA must return 9,000,000 shares soon... Cave In Temptor 10/04/15 02:29:11 PM
#15050   I wonder what the going rate is on KingDMC 10/04/15 02:19:35 PM
#15049   Hilarious. KingDMC 10/04/15 02:18:40 PM
#15048   Closed above $3.25 so are you bullish lmao? KingDMC 10/04/15 02:18:18 PM
#15047   Interesting Monday: Resident doom-sayer bullish on MNKD since Cave In Temptor 10/04/15 02:14:41 PM
#15046   see you all on Monday .... TREND1 10/04/15 02:11:03 PM
#15045   Isn't it nice being retired Y47! We can Denise Chanterelle 10/04/15 02:10:34 PM
#15044   All I hear is noise and Ruffled feathers. KingDMC 10/04/15 02:07:44 PM
#15043   Oh please. And trend isn't biased to the KingDMC 10/04/15 02:04:36 PM
#15042   Do you know if IBB has to sell exwannabe 10/04/15 02:03:33 PM
#15041   I congratulate you on a great move investing yosemite47 10/04/15 02:00:16 PM
#15040   Aloha Crew: Sanofi is not going anywhere. Denise Chanterelle 10/04/15 01:58:51 PM
#15039   BoA must return 9 M shares or else... exwannabe 10/04/15 01:52:27 PM
#15038   I see you agree with ART HILL. TREND1 10/04/15 01:49:03 PM
#15037   Aloha Roblorane, and welcome to the i-hub Board. Denise Chanterelle 10/04/15 01:46:35 PM
#15036   IMO, Mannkind investors should stop obsessing about Denise Chanterelle 10/04/15 01:44:20 PM